ascopubs.org

Cost-effectiveness analysis using a Markov model assessing the addition of bevacizumab to paclitaxel in HER2-negative metastatic breast cancer patients.

Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer. This is an ASCO Meeting Abstract from ...
ascopubs.org

A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer.

A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a ...
JSTOR Daily

A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for "glioblastoma ...

This is a preview. Log in through your library . Abstract Background Cost-effectiveness analyses of treatments for glioblastoma multiforme (GBM) have mostly used state transition Markov models with ...
JSTOR Daily

The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model

Purpose Adenoid hypertrophy (AH) is common among young children. Adenoid-based surgery and drug therapy could be applied for symptomatic AH patients, yet the treatment decision is difficult to make ...
The American Journal of Managed Care

Evaluating Cost-Effectiveness of Different Endovascular Therapy [EVT] Strategies

Therapeutic and financial considerations of EVT are explored by a medical expert. This is a video synopsis/summary of a Post Conference Perspectives involving Kevin Sheth, MD. Sheth provides ...